An alternative splice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation.
Alternative splicing of mRNA can generate protein isoforms that are preferentially expressed in different tissues or during different states of cell differentiation or activation. Protein isoforms may have different functions. In this study, we cloned, expressed, and tested functional effects of a naturally occurring splice variant of human IL-4, called IL-4 delta 2. In IL-4 delta 2, the second exon of IL-4 is omitted by alternative splicing, with exons 1, 3, and 4 joined in an open reading frame. We found that IL-4 delta 2 RNA is expressed in the PBMC of all donors tested, usually in lower amounts than IL-4 RNA. In contrast, IL-4 delta 2 RNA is expressed in much higher levels than IL-4 RNA in thymocytes and bronchoalveolar lavage cells, suggesting tissue specificity of expression. IL-4 delta 2 cDNA was expressed in yeast. Recombinant human (rh) IL-4 delta 2 was partially purified and found to be glycosylated, with a protein core of 13 to 15 kDa. Unlike rhIL-4, rhIL-4 delta 2 did not act as a costimulator for T cell proliferation. However, rhIL-4 delta 2 inhibited the ability of rhIL-4 to act as a T cell costimulator. Inhibition was independent of glycosylation and was not mediated by toxicity. Iodinated IL-4 delta 2 was found to bind specifically to human PBMC and tumor lines known to express IL-4 receptors. Excess unlabeled IL-4 inhibited cellular binding of labeled IL-4 delta 2. Thus, rhIL-4 delta 2 is a naturally occurring splice variant of IL-4 that is preferentially expressed in the thymus and airways and inhibits function of complete IL-4. The balance between IL-4 and IL-4 delta 2 may be important in the regulation of IL-4 effects.
Atamas
S P
SP
Department of Medicine, University of Maryland at Baltimore, USA.
Choi
J
J
Yurovsky
V V
VV
White
B
B
D000595:Amino Acid Sequence; D015703:Antigens, CD / Q000187:drug effects / Q000378:metabolism; D001483:Base Sequence; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002478:Cells, Cultured; D003001:Cloning, Molecular; D018076:DNA, Complementary / Q000235:genetics; D003864:Depression, Chemical; D005091:Exons / Q000235:genetics; D006801:Humans; D015847:Interleukin-4 / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000302:isolation & purification / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects*; D008969:Molecular Sequence Data; D016366:Open Reading Frames; D009928:Organ Specificity; D012326:RNA Splicing; D012333:RNA, Messenger / Q000235:genetics; D018123:Receptors, Interleukin / Q000187:drug effects / Q000378:metabolism; D019948:Receptors, Interleukin-4; D011993:Recombinant Fusion Proteins / Q000302:isolation & purification / Q000494:pharmacology; D012137:Respiratory System / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects*; D013950:Thymus Gland / Q000378:metabolism
D015703:Antigens, CD; D018076:DNA, Complementary; D012333:RNA, Messenger; D018123:Receptors, Interleukin; D019948:Receptors, Interleukin-4; D011993:Recombinant Fusion Proteins; D015847:Interleukin-4